Search

Your search keyword '"Champiat, S."' showing total 235 results

Search Constraints

Start Over You searched for: Author "Champiat, S." Remove constraint Author: "Champiat, S."
235 results on '"Champiat, S."'

Search Results

201. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

203. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

204. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

205. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

206. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

207. [Cardiac and vascular toxicity of chemotherapies].

208. Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication.

209. Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

210. Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

211. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.

212. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

213. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

214. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

215. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.

216. Immune-related bone marrow failure following anti-PD1 therapy.

218. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

219. Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.

221. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

222. The development of immunotherapy in older adults: New treatments, new toxicities?

223. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

224. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

225. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

226. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

227. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.

228. [Breaking immune tolerance in cancer].

229. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.

230. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

231. [Immunotherapies and targeted therapies in medical oncology].

232. T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

233. [Immune-checkpoints: the new anti-cancer immunotherapies].

234. Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

235. Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses.

Catalog

Books, media, physical & digital resources